Aclarion, Inc. - Warrant (OQ:ACONW)
Business Focus: N/A
Apr 25, 2024 09:14 am ET
Aclarion’s Nociscan Solution to Play Key Role in Groundbreaking LIFEHAB Trial Evaluating the Diagnosis and Treatment of Chronic Low Back Pain
via NewMediaWire -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW),a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of...
Mar 04, 2024 08:00 am ET
Aclarion Announces Publication of Compelling Peer-Reviewed Data in International Journal of Spine Surgery Supporting Nociscan as a Gold Standard for Noninvasive Identification of Painful Lumbar Discs
via NewMediaWire -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of...
Feb 27, 2024 03:22 pm ET
Aclarion Announces Closing of $3.0 Million Public Offering
via NewMediaWire - Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of...
Feb 26, 2024 09:15 am ET
Aclarion Announces Pricing of $3.0 Million Public Offering
via NewMediaWire -- Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of...
Feb 05, 2024 08:00 am ET
Aclarion Announces Successful Financings; Plans to Launch CLARITY Trial and Provides Update on Next Steps of Alphatec Strategic Partnership
via NewMediaWire -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of...
Jan 22, 2024 08:00 am ET
Aclarion Expands Nociscan Access Into Phoenix With Key Opinion Leader Surgeon Advisor Juan Uribe, MD
via NewMediaWire – Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of...
Jan 17, 2024 08:00 am ET
Aclarion Announces Updated Product Release That Expands MRI Scanner Access for Nociscan Solution
via NewMediaWire -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of...
Jan 08, 2024 08:00 am ET
Aclarion and ATEC Execute Strategic Partnership Agreement to Advance Commercialization of Nociscan
via NewMediaWire -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of...
Jan 02, 2024 12:00 pm ET
Aclarion Announces Reverse Stock Split
via NewMediaWire -- Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of...
Nov 27, 2023 08:00 am ET
Aclarion Announces Key Commercial Milestone With Completion of 1,000 Nociscan Exams
via NewMediaWire -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of...
Nov 08, 2023 08:00 am ET
Aclarion Announces Achievement of Goal to Enroll 10 Leading Spine Surgery Key Opinion Leaders (KOLs) to Support Nociscan Adoption
via NewMediaWire – Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of...
Nov 06, 2023 08:00 am ET
Aclarion Expands Immediate Nociscan Access Into New York City With Tenth Key Opinion Leader Surgeon Advisor Addition Roger Hartl, MD
via NewMediaWire -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of...
Nov 01, 2023 08:00 am ET
Aclarion Presents at the NIH HEAL Initiative Fall Meeting
via NewMediaWire – Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of...
Oct 25, 2023 08:30 am ET
Aclarion Announces Signing of Commercial Agreement With Porter Hospital, an AdventHealth facility, to Bring Nociscan Technology to Denver
via NewMediaWire – Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of...
Oct 24, 2023 08:45 am ET
Aclarion Announces Nociscan® Cost-Effectiveness Poster Presented at 45th Annual SMDM Meeting
via NewMediaWire – Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of...
Oct 23, 2023 07:00 am ET
Aclarion Announces Signing Strategic Partnership Letter of Intent With ATEC to Advance Commercialization of Nociscan
via NewMediaWire -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of...
Oct 02, 2023 08:00 am ET
Aclarion Provides Updated Investor Presentation and Corporate Update
via NewMediaWire -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of...
Aug 25, 2023 04:10 pm ET
Aclarion, Inc. Announces Filing of Delayed 10-Q Quarterly Report
via NewMediaWire -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of...
Jun 14, 2023 11:27 am ET
Aclarion Announces New Commercial Engagement with The Imaging Center, Grand Rapids, MI
via NewMediaWire – Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of...
Jun 08, 2023 07:30 am ET
Aclarion Announces Statistically Significant Nociscan® Cost-Effectiveness Abstract Presented at ISASS Annual Meeting
via NewMediaWire – Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of...
May 30, 2023 07:30 am ET
Aclarion Announces New Engagement with The London Clinic and London Spine Clinic
via NewMediaWire – Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of...
May 23, 2023 07:30 am ET
Aclarion’s Key Opinion Leader Program Adds Ninth Surgeon Advisor With Addition of Dean Karahalios, MD
via NewMediaWire – Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of...
May 23, 2023 07:00 am ET
Aclarion, Inc. Announces Delayed 10-Q Filing
via NewMediaWire – Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of...
May 19, 2023 07:30 am ET
Aclarion Announces Non-Convertible Debt Financing to Achieve Three Critical Catalysts
via NewMediaWire – Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of...
May 02, 2023 07:00 am ET
Aclarion Appoints Nicholas Theodore, MD as Principal Investigator for CLARITY Post-Market Trial Evaluating Nociscan in the Diagnosis and Treatment of Chronic Low Back Pain
via NewMediaWire – Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of...
Apr 28, 2023 11:20 am ET
Aclarion to Host Thought Leadership Symposium at SPINEWEEK 2023
via NewMediaWire – Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of...
Apr 24, 2023 07:00 am ET
Aclarion Announces Publication of 2YR Outcomes in Groundbreaking Clinical Trial
via NewMediaWire -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of...
Mar 07, 2023 09:19 am ET
Aclarion Announces Alpesh Patel MD MBA as a Key Opinion Leader Physician Advisor
via NewMediaWire – Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of...
Feb 15, 2023 07:00 am ET
Aclarion Supports Thought Leadership at the 2nd Annual Sonntag Spine Symposium
via NewMediaWire – Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of...
Jan 31, 2023 10:01 am ET
Gregory Basil MD to Join Aclarion as a Key Opinion Leader Surgeon Advisor
via NewMediaWire -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW),a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of...
Jan 17, 2023 08:29 am ET
Aclarion Appoints George Frey MD as Seventh Key Opinion Leader Surgeon Advisor
via NewMediaWire -- Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of...
Dec 22, 2022 10:36 am ET
Dr. Christopher Ames to Join Aclarion as a Key Opinion Leader Surgeon Advisor
via NewMediaWire -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of...
Dec 21, 2022 10:23 am ET
Aclarion’s Key Opinion Leader Program Adds Fifth Surgeon Advisor with Addition of Eric Potts, MD
via NewMediaWire -- Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of...
Dec 19, 2022 08:33 am ET
Aclarion Adds to Growing Key Opinion Leader Program with Juan Uribe M.D. as a Surgeon Advisor
via NewMediaWire -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of...
Oct 25, 2022 07:00 am ET
Aclarion, Inc. Releases Updated Investor Presentation In Connection with Appearance at LD Micro Main Event XV
BROOMFIELD, CO / ACCESSWIRE / October 25, 2022 / Aclarion, Inc. (NASDAQ:ACON)(NASDAQ:ACONW) ("Aclarion" or the "Company"), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain (CLBP), will be presenting at the 15th annual LD Micro Main Event on Tuesday, October 25th at 9:00 AM PT at the Luxe Sunset Boulevard Hotel in Los Angeles. Executive Chairman, Jeff Thramann will be presenting an overview of the Company and providing a business u
Oct 24, 2022 07:00 am ET
Dr. Sigurd Berven to join Aclarion as a Key Opinion Leader Surgeon Advisor
BROOMFIELD, CO / ACCESSWIRE / October 24, 2022 / Aclarion, Inc., ("Aclarion" or the "Company") (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today that Sigurd Berven M.D., Chief of Spine Service, Orthopaedic Surgery at University of California at San Francisco will advise the company as a key opinion leader (KOL) nationally.
Oct 10, 2022 07:05 am ET
Aclarion Announces Participation at the NASS 37th Annual Meeting
Nociscan utilized within unprecedented NIH HEAL Initiative featured at NASS 2022
Oct 03, 2022 07:03 am ET
John Keller M.D. to Join Aclarion as a Key Opinion Leader Surgeon Advisor
Aclarion Key Opinion Leader program supports focused strategy of building strong clinical evidence and payer community advocacy to drive adoption of NociscanTM solution
Sep 19, 2022 07:03 am ET
Nociscan Selected for Inclusion in Pivotal National Institutes of Health (NIH) Study for Low Back Pain
NIH funded Biomarkers for Evaluating Spine Treatments (BEST) Trial launching this quarter
Jul 20, 2022 07:00 am ET
Aclarion Announces Start of Healthcare Economic Analysis Study to Evaluate Financial Impact of Nociscan
Initial findings from the EVAL study are expected to be released in Q4 2022
Jun 22, 2022 07:00 am ET
Aclarion to Present 2-year Follow Up Data on Pivotal Clinical Trial Linking Nociscan to Better Surgical Outcomes for Discogenic Low Back Pain
Superior Clinical Outcomes for NociscanTM Proving to be Durable at Two Years
Apr 26, 2022 09:15 pm ET
Aclarion, Inc. Announces Closing of $9.4 Million Initial Public Offering
SAN MATEO, CA / ACCESSWIRE / April 26, 2022 / Aclarion, Inc. ("Aclarion" or the "Company") (NASDAQ:ACON) (NASDAQ:ACONW), a healthcare technology company that leverages Magnetic Resonance Spectroscopy ("MRS"), artificial intelligence and a proprietary biomarker to optimize clinical treatments for low back and neck pain, today announced the closing of its previously announced initial public offering of 2,165,000 shares of its common stock and accompanying warrants to purchase up to 2,165,000 shares of common stock. Each share of com
Apr 21, 2022 07:45 pm ET
Aclarion, Inc. Announces Listing on Nasdaq and Pricing of $9.4 Million Initial Public Offering
SAN MATEO, CA / ACCESSWIRE / April 21, 2022 / Aclarion, Inc. ("Aclarion" or the "Company") (NASDAQ:ACON)(NASDAQ:ACONW), a healthcare technology company that leverages Magnetic Resonance Spectroscopy ("MRS"), artificial intelligence and a proprietary biomarker to optimize clinical treatments for low back and neck pain, today announced the pricing of its initial public offering of 2,165,000 shares of its common stock and accompanying warrants to purchase up to 2,165,000 shares of common stock. Each share of common stock is being sol
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Canadianinsider.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Read more...Insider information is based on filings made on the System
for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission.Read less
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Interactive technical study charts by TradingView. Copyright © 2024 INK Research Corp. All rights reserved. All trade-marks or trade names not owned by INK Research Corp. are the property of their respective owners.